A pivotal Phase III clinical trial demonstrated a substantial visual improvement in a twelve-month period among patients identified with biallelic RPE65 gene mutations associated with retinal dystrophy, subsequent to Luxturna therapy (Russell et al., 2017). The gene discussed is RPE65; the disease is Retinal dystrophy.